-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1188 The Nonsynonymous-Single-Nucleotide Polymorphism (ns-SNP) 353 R>q in the Coagulation Factor VII (FVII) Gene, F7, is Associated with Decreased Plasma FVII Levels and a Decreased Risk of Coronary Heart Disease (CHD) in Mexican Americans of South Texas

Program: Oral and Poster Abstracts
Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Fundamental Science, thromboembolism, Diseases, thrombotic disorders
Saturday, December 10, 2022, 5:30 PM-7:30 PM

Kanisha Patel, B.S.1*, Vincent P. Diego, Ph.D.2,3*, Alberto D. Lopez, B.S.4*, Marcio A. Almeida, Ph.D.3,5*, Joanne E. Curran, Ph.D.3,5*, Miguel Escobar, MD6,7*, Jerry S. Powell, M.D.8,9, Donna M. Lehman, Ph.D.10*, Ralph A DeFronzo, M.D.11*, Sarah Williams-Blangero, Ph.D.3,5*, Ravi Duggirala, Ph.D.12*, Laura Almasy, Ph.D.13*, John Blangero, Ph.D.3,5* and Tom E. Howard, MD, PhD3,8,14,15*

1Department of Human Genetics, University of Texas Rio Grande Valley, Edinburg, TX
2South Texas Diabetes and Obesity Institute, University of Texas Rio Grande Valley School of Medicine, BROWNSVILLE, TX
3Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Brownsville, TX
4Department of Human Genetics, University of Texas Rio Grande Valley School of Medicine, Edinburg
5South Texas Diabetes and Obesity Institute, University of Texas Rio Grande Valley, Brownsville, TX
6McGovern Medical School and Gulf States Hemophilia and Thrombophilia Center, University of Texas Health Science Center, Houston Medical School, Houston, TX
7Gulf States Hemophilia and Thrombophilia Center, Houston, TX
8Haplogenics, Brownsville, TX
9Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, The University of California at Davis, Davis, CA
10School of Medicine, University of Texas Health Science Center - San Antonio, San Antonio, TX
11University of Texas Health Science Center - San Antonio, San Antonio, TX
12Department of Human Genetics, University of Texas Rio Grande Valley School of Medicine, Edinburg, TX
13Department of Genetics, University of Pennsylvania School of Medicine, Philadelphia, PA
14Department of Pathology and Laboratory Medicine, VA Valley Coastal Bend Healthcare System, Harlingen, TX
15South Texas Diabetes and Obesity Institute, The University of Texas Rio Grande Valley, Brownsville, TX

We performed an exome-wide scan of known genetic variants to identify any potentially associated with plasma levels of FVII coagulant activity (FVII:C) in Mexican Americans from South Texas.

Recent meta-analyses of the 353 R>Q ns-SNP (rs6046) in F7 have reported that the Q-allele is associated with a decreased risk of CHD. In our study of the genetic determinants of cardiovascular disease (CVD) in Mexican Americans of South Texas, we performed an exome-wide scan in relation to plasma FVII:C levels in 784 individuals. Accounting for age, sex, and their interactions as confounders in linear mixed model, we found a heritability of 30% for FVII:C levels (p=1.1E-08), and that the 353 R>Q ns-SNP was the only variant showing exome-wide significance (p=2.1E-09; Figure 1A). Though the quantile-quantile distribution of the p-values from all the exome-wide tests is not shown, the p-value distribution revealed that: (i) there is no systematic bias that may act to skew the p-values; and (ii) the lone exception in agreement between observed and expected quantiles is due to the 353 R>Q signal, which strongly suggests a truly significant effect. Consistent with the meta-analysis reports, the regression coefficient for the polymorphism as a predictor of FVII:C levels showed them to be increasing from the homozygous for the major G-allele (G/G: Arg/Arg), to the heterozygous individuals (G/A: Arg/Gln), to the individuals homozygous for the minor A-allele (A/A: Gln /Gln) (Figure 1B). We also investigated if the 353 R>Q ns-SNP is associated with our CHD variable. Using a statistical genetic model for the liability to disease conditional on a threshold, which is equivalent to a probit mixed model, we found that 353 R>Q is significantly associated with a reduction in the risk of CHD (p=0.005) (data not shown). Although not shown here, due to space limitations, the effect of the F7 variant is to upwardly displace the liability threshold to the right, which results in a reduced prevalence of CHD. While the reduction is indeed a small change, it is statistically significant, nonetheless. Moreover, our observed effect size in terms of CHD risk is consistent with the widely held view that CHD has a multifactorial etiology involving a complex combination of environmental risk factors and genes with small effects sizes.

In conclusion, we found that F7 353 R>Q ns-SNP is pleiotropically associated with FVII:C levels and risk of CHD.

Disclosures: Escobar: Genentech: Honoraria; UniQure: Honoraria; Hemobiologics/LFB: Honoraria; Kedrion: Honoraria; Sanofi: Honoraria; Novo Nordisk: Honoraria; Bayer: Honoraria; CSL Behring: Honoraria; Takeda: Honoraria; Pfizer: Honoraria; The National Hemophilia Foundation: Honoraria; BioMarin: Honoraria.

*signifies non-member of ASH